SCHEMBL5324141

SCHEMBL5324141

Cc1cccc(CC(N)CCC(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.46
ENPEP Q07075 1/20 0.46
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
CPA3 P15088 1/20 0.44
CTBP2 P56545 1/20 0.43
POLB P06746 1/20 0.43
SLC15A1 P46059 1/20 0.43
S1PR2 O95136 1/20 0.43
S1PR1 P21453 1/20 0.43
S1PR3 Q99500 1/20 0.43
FFAR1 O14842 1/20 0.43
CTSB P07858 1/20 0.42
TACR1 P25103 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
LTA4H P09960 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5321285 0.87 S1PR2 (0.55) THRATHRBFFAR4CTBP2S1PR2
SCHEMBL29478403 0.84 ANPEP (0.48) ANPEPENPEPCTBP2POLBFFAR1
SCHEMBL2028584 0.84 ANPEP (0.48) ANPEPENPEPCTBP2POLBFFAR1
SCHEMBL29478376 0.84 ANPEP (0.48) ANPEPENPEPCTBP2POLBFFAR1
SCHEMBL2033289 0.84 ANPEP (0.48) ANPEPENPEPCTBP2POLBFFAR1
SCHEMBL2028585 0.84 ANPEP (0.48) ANPEPENPEPCTBP2POLBFFAR1
SCHEMBL22734406 0.83 GRIA2 (0.52) ANPEPENPEPCPA3CTBP2SLC15A1
SCHEMBL30810168 0.83 GRIA2 (0.52) ANPEPENPEPCPA3CTBP2SLC15A1
SCHEMBL289176 0.83 ANPEP (0.47) ANPEPENPEPTHRATHRBCPA3
SCHEMBL27999569 0.83 ANPEP (0.47) ANPEPENPEPTHRATHRBCPA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 ANPEP 1314/4885ENPEP 1028/4885THRA 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.